Respiratory Syncytial Virus Infection
- Author: Leonard R Krilov, MD; Chief Editor: Russell W Steele, MD more...
Respiratory syncytial virus (RSV) (see the image below) is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children. Each year, 4-5 million children younger than 4 years acquire an RSV infection, and more than 125,000 are hospitalized annually in the United States because of this infection.
Essential update: Updated guidelines for palivizumab RSV prophylaxis released
The American Academy of Pediatrics has released updated guidelines addressing palivizumab prophylaxis for respiratory syncytial virus (RSV).
According to the updated recommendations, palivizumab prophylaxis for RSV should be limited to infants born before 29 weeks' gestation and to infants with chronic illness such as congenital heart disease or chronic lung disease. Other recommendations include the following:
Give infants who qualify for prophylaxis in the first year of life no more than five monthly doses of palivizumab (15 mg/kg per dose) during the RSV season
In the second year of life, palivizumab prophylaxis is recommended only for children who needed supplemental oxygen for 28 days or more after birth and who continue to need medical intervention (supplemental oxygen, chronic corticosteroid, or diuretic therapy).
Clinicians may consider prophylaxis for children younger than 24 months if they will be profoundly immunocompromised during the RSV season.
Signs and symptoms
Patients with RSV infection may present with the following symptoms:
Fever (typically low-grade)
Sepsislike presentation or apneic episodes (in very young infants)
Physical examination of the infant with RSV-related LRTI may reveal the following:
Evidence of diffuse small airway disease
Associated otitis media (viral, bacterial, or both)
Dehydration (assessed by evaluating skin turgor, capillary refill, and mucous membranes)
RSV LRTI in infancy may be linked with subsequent reactive airway disease, although this association remains controversial.
See Presentation for more detail.
Laboratory studies generally are not indicated in the infant with bronchiolitis who is comfortable in room air, well hydrated, and feeding adequately. When warranted, nonspecific laboratory studies may include the following:
Complete blood count (CBC)
Serum electrolyte concentrations
Specific tests for RSV may be indicated for therapeutic decision making, isolation of patients, and educating parents and staff. Specific diagnostic tests for confirming RSV infection include the following:
Polymerase chain reaction (PCR) assay
Chest radiography is frequently obtained in children with severe RSV infection, but for the most part, typical findings are neither specific to RSV infection nor predictive of the course or outcome.
See Workup for more detail.
Supportive care is the mainstay of therapy for RSV infection. Although corticosteroids are sometimes given, the available clinical data do not support their use in the treatment of typical RSV bronchiolitis.
Pharmacologic therapies for RSV infection include the following:
Bronchodilators – These benefit at least a subset of patients with RSV-related LRTI
Alpha agonists – These have been used during acute bronchiolitis episodes, though their efficacy has not been established
Ribavirin – This agent is primarily reserved for patients with significant underlying risk factors and severe acute RSV disease (eg, transplant recipients)
The following agents have been used in passive immunization to protect against RSV infection:
RSV immune globulin intravenous (RSV-IGIV; no longer being manufactured)
Palivizumab (FDA-approved for prophylaxis in children at high risk for severe RSV disease)
According to American Academy of Pediatrics (AAP) guidelines for RSV prophylaxis, the following are candidates for palivizumab prophylaxis:
Infants younger than 24 months who have hemodynamically significant congenital heart disease (cyanotic or acyanotic lesions) or who have chronic lung disease and are off oxygen or pulmonary medications for less than 6 months at the start of the RSV season
Premature infants born at 28 weeks’ gestational age or less who are younger than 1 year chronological age at the start of the RSV season; once treatment is initiated, it should continue throughout the season and not stop at age 1 year
Premature infants born at 29-32 weeks’ gestational age who are younger than 6 months' chronological age at the start of the RSV season; once treatment is initiated, it should continue throughout the season and not stop at age 6 months
Infants born at 32-35 weeks’ gestational age who are younger than 3 months’ chronological age at the start of or during the RSV season and who either attend child care or have one or more siblings or other children younger than 5 years living permanently in the same household; prophylaxis should be provided only until age 3 months
Other measures proposed for preventive purposes include the following:
Vaccination (unsuccessful to date)
Vitamin D supplementation (supplementation during pregnancy may ameliorate RSV LRTI during infancy)
Infection with respiratory syncytial virus (RSV; see the image below), which manifests primarily as bronchiolitis or viral pneumonia, is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children.
The clinical entity of bronchiolitis was described at least 100 years ago. In 1956, Morris and colleagues initially isolated RSV from chimpanzees with upper respiratory tract infections (URTIs) and identified the virus as the causative agent of most epidemic bronchiolitis cases. Subsequently, RSV has been associated with bronchiolitis and LRTI in infants. Multiple epidemiologic studies have confirmed the role of this virus as the leading cause of LRTI in infants and young children.
The peak incidence of severe RSV disease is at age 2-8 months. Overall, 4-5 million children younger than 4 years acquire an RSV infection each year, and more than 125,000 are hospitalized annually in the United States because of this infection. Virtually all children have had at least 1 RSV infection by the age of 3 years. In view of the prevalence and potential severity of this condition, it is not surprising that the World Health Organization (WHO) has targeted RSV for vaccine development.
This article reviews aspects of the virology, epidemiology, clinical course, diagnosis, treatment, and prevention of RSV-related illness.
RSV infection is limited to the respiratory tract. Initial infection in young infants or children frequently involves the lower respiratory tract and most often manifests as the clinical entity of bronchiolitis. Inoculation of the virus occurs in respiratory epithelial cells of the upper respiratory tract. Spread of the virus down the respiratory tract occurs through cell-to-cell transfer of the virus along intracytoplasmic bridges (syncytia) from the upper to the lower respiratory tract.
The illness may begin with upper respiratory symptoms and progress rapidly over 1-2 days to the development of diffuse small airway disease characterized by cough, coryza, wheezing and rales, low-grade fever (< 101°F), and decreased oral intake. A family history of asthma or atopy is frequently obtained.[3, 4] In more advanced disease, retractions and cyanosis may be noted, and as many as 20% of patients may develop higher temperatures.
The incidence of concomitant or secondary serious bacterial infection in association with RSV infection appears to be quite low (< 1%), with the exception of otitis media, which may occur in as many as 40% of cases. In very young infants, apnea out of proportion to respiratory signs and symptoms may be present, and in infants younger than 6 weeks, a relatively nonspecific sepsislike picture has been described.
Reinfection with RSV occurs at all ages; however, with recurrent infection and increasing age, RSV infections are more likely to be limited to the upper respiratory tract. RSV URTI is more severe than the common cold, as evidenced by the 7- to 10-day duration of illness and by the finding from one study of adults with RSV that the mean absence from work is 6 days. Studies have also demonstrated severe RSV disease in elderly persons.
In the community setting, a number of factors have been associated with an increased risk of acquiring RSV disease, including the following:
Older siblings in preschool or school
Crowding and lower socioeconomic status
Exposure to environmental pollutants (eg, cigarette smoke)
Multiple birth sets (especially triplets or greater)
In infants with RSV infection, the following factors have been correlated with more severe disease and the need for hospitalization.
Age younger than 3 months at the time of infection
Chronic lung disease
Congenital heart disease
Congenital immunodeficiency (eg, severe combined immunodeficiency [SCID])
Severe neuromuscular disease
Toxic appearance at time of presentation
Respiratory rate higher than 70 breaths/min on room air
Atelectasis or pneumonitis on chest radiography
Oxygen saturation lower than 95% on room air
Although infants in these groups are at higher risk for severe RSV disease than are normal full-term infants in terms of percentages, many more children in the normal full-term group are admitted to the hospital; thus, most admissions for RSV disease occur in otherwise normal infants. A family history of asthma and genetic factors are also correlated with more severe RSV disease, though the exact relations and mechanisms have not been elucidated.
RSV LRT infection develops annually in 4-5 million children, and more than 125,000 children are admitted per year for RSV-related illness. Seasonal variations in incidence are observed (see the image below). Reinfection occurs throughout life, with the disease generally limited to the upper respiratory tract in persons older than 3 years. Severe RSV disease has been reported in older children and adults with SCID (eg, bone marrow transplantation), and RSV disease of the lower respiratory tract has been reported in elderly persons.
Worldwide, RSV infection is prevalent, with clinical manifestations and early occurrence of RSV LRTI comparable to those seen in the United States.
Severe RSV disease is primarily a disease of young infants and children, with a peak occurrence at the age of 2-8 months. Reinfection with RSV occurs throughout life, with disease becoming increasingly limited to the upper respiratory tract with advancing age. URT, as discussed above. Although boys and girls are equally affected by milder RSV disease, males are approximately twice as likely to be hospitalized for RSV disease. All races appear to be susceptible to RSV, showing similar disease patterns.
Children hospitalized secondary to RSV infection typically recover and are discharged in 3-4 days. High-risk infants remain hospitalized longer and have higher rates of admission to the intensive care unit (ICU) and of mechanical ventilation.
Even in children hospitalized with RSV infection, mortality is less than 1%, and fewer than 500 deaths per year are attributed to RSV in the United States. However, in select groups of high-risk patients, appreciable mortality and increased morbidity still may result from this infection.[8, 9, 10]
Infants with chronic lung disease of infancy (ie, bronchopulmonary dysplasia), congenital heart disease, or marked prematurity when hospitalized for this disease may have a 3-5% mortality rate. Additionally, such infants and patients with immunodeficient states have been shown to spend, on average, twice as long in the hospital as other patients with RSV infection (7-8 days vs 3-4 days in normal full-term infants).
Additionally, children hospitalized for RSV disease during infancy have higher rates of subsequent wheezing than age-matched controls not hospitalized for this condition over the next 10 or more years. Whether RSV itself leads to alterations of airways or immune responses contributing to these subsequent events or is just a marker for children at risk for reactive airway disease remains incompletely understood.
Barclay, L. AAP: Palivizumab RSV Prophylaxis Guidelines Updated. Medscape Medical News. Available at http://www.medscape.com/viewarticle/828957. Accessed: August 4, 2014.
Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999 Oct 20. 282(15):1440-6. [Medline].
Perez-Yarza EG, Moreno A, Lazaro P, Mejias A, Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J. 2007 Aug. 26(8):733-9. [Medline].
Welliver RC. Bronchiolitis and infectious asthma. Feigin RD, Cherry JD, Demmler-Harrison G J, Kaplan SLeds. Textbook of Pediatric Infectious Diseases. 6th edition. Philadelphia, PA: Saunders Elsevier; 2009. 277-288.
Oray-Schrom P, Phoenix C, St Martin D, Amoateng-Adjepong Y. Sepsis workup in febrile infants 0-90 days of age with respiratory syncytial virus infection. Pediatr Emerg Care. 2003 Oct. 19(5):314-9. [Medline].
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28. 352(17):1749-59. [Medline].
Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004 Sep. 23(9):815-20. [Medline].
Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003 Nov. 143(5 Suppl):S127-32. [Medline].
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8. 289(2):179-86. [Medline].
Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5. 360(6):588-98. [Medline].
Paes B, Mitchell I, Li A, Lanctôt KL. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis. 2012 May 1. [Medline].
Winterstein AG, Hampp C, Saidi A. Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf. 2012 Jan. 21(1):53-60. [Medline].
Corneli HM, Zorc JJ, Mahajan P, Majahan P, Shaw KN, Holubkov R. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med. 2007 Jul 26. 357(4):331-9. [Medline].
Hall CB, Douglas RG Jr. Modes of transmission of respiratory syncytial virus. J Pediatr. 1981 Jul. 99(1):100-3. [Medline].
Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytialvirus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003 Oct. 143(4):532-40. [Medline].
Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998 Sep. 102(3 Pt 1):531-7. [Medline].
[Guideline] Committee on Infectious Diseases; American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. 2003 Red Book: Report of the Committee on Infectious Diseases. 2003:523-528.
From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009 Dec. 124(6):1694-701. [Medline].
Rietveld E, Steyerberg EW, Polder JJ, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child. 2010 Jul. 95(7):493-8. [Medline].
Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007 Jul. 151(1):34-42, 42.e1. [Medline].
Yi H, Lanctôt KL, Bont L, Bloemers BL, Weijerman M, Broers C, et al. Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study. Pediatrics. 2014 May 5. [Medline].
Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010 Jan. 125(1):e35-51. [Medline].
Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev. 1998 Jul. 11(3):430-9. [Medline].
Belderbos ME, Houben ML, Wilbrink B, et al. Cord blood vitamin d deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011 Jun. 127(6):e1513-20. [Medline].
Hall CB, Dougla RG, Geiman JM, Messner MK. Nosocomial respiratory syncytial virus infections. N Engl J Med. 1975. 293:1343-6. [Medline].
Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000 Dec. 137(6):865-70. [Medline].
Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015 Apr. 169 (4):341-8. [Medline].
Harding A. Spreading Out Palivizumab Shots Improves RSV Protection. Reuters Health Information. Available at http://www.medscape.com/viewarticle/840348. February 25, 2015; Accessed: June 26, 2015.
Ambrose CS, Anderson EJ, Simoes EA, et al. Respiratory syncytial virus disease in preterm infants in the US born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014 Jun. 33(6):576-82. [Medline]. [Full Text].
AstraZeneca. New study reveals significant burden of RSV disease among U.S. preterm infants born at 32-35 weeks. Medical News Today. June 5, 2014. [Full Text].
Tabarani CM, Bonville CA, Suryadevara M, Branigan P, Wang D, Huang D, et al. Novel Inflammatory Markers, Clinical Risk Factors, and Virus Type Associated with Severe Respiratory Syncytial Virus Infection. Pediatr Infect Dis J. 2013 Jun 25. [Medline].